EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium

Takafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, Satoshi Katayama, Takuya Tsujino, Ryoichi Maenosono, Shingo Toyoda, Takuhisa Nukaya, Hirofumi Morinaka, Keita Tamura, Wataru Fukuokaya, Fumihiko Urabe und 10 weitere

Cancer Immunology, Immunotherapy · 25.02.2026 · 75 (3)

DOI: 10.1007/s00262-025-04288-6 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 25.02.2026. Verfasst von Takafumi Yanagisawa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan. t.yanagisawa.jikei@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Anilides, Quinolines, Kidney Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellAnilidesQuinolinesKidney NeoplasmsAntibodies, Monoclonal, HumanizedPyridinesAntineoplastic Combined Chemotherapy ProtocolsNivolumabHumansPhenylurea CompoundsFemaleMaleRetrospective StudiesAgedMiddle AgedAged, 80 and overTreatment OutcomeAdultNeoplasm Metastasis

Stichwörter der Autor:innen

CabozantinibImmune checkpoint inhibitorLenvatinibMetastatic renal cell carcinomaNivolumabPembrolizumab

Substanzen

Phenylurea CompoundsAnilidesQuinolinescabozantiniblenvatinibAntibodies, Monoclonal, HumanizedPyridinespembrolizumabNivolumab

Autor:innen und Institutionen

  • Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan. t.yanagisawa.jikei@gmail.com.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. t.yanagisawa.jikei@gmail.com.
  • Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.

Zitieren

APA

Yanagisawa, T., Mori, K., Kawada, T., Katayama, S., Tsujino, T., Maenosono, R., Toyoda, S., Nukaya, T., Morinaka, H., Tamura, K., Fukuokaya, W., Urabe, F., Murakami, M., Bekku, K., Takahara, K., Fujita, K., Azuma, H., Araki, M., Inamoto, T., …, & JK-FOOT study group (2026). A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium. Cancer Immunology, Immunotherapy, 75(3). https://doi.org/10.1007/s00262-025-04288-6

Vancouver

Yanagisawa T, Mori K, Kawada T, Katayama S, Tsujino T, Maenosono R, et al. A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium. Cancer Immunology, Immunotherapy. 2026;75(3). doi:10.1007/s00262-025-04288-6

BibTeX
@article{Yanagisawa2026,
  author = {Yanagisawa, Takafumi and Mori, Keiichiro and Kawada, Tatsushi and Katayama, Satoshi and Tsujino, Takuya and Maenosono, Ryoichi and Toyoda, Shingo and Nukaya, Takuhisa and Morinaka, Hirofumi and Tamura, Keita and Fukuokaya, Wataru and Urabe, Fumihiko and Murakami, Masaya and Bekku, Kensuke and Takahara, Kiyoshi and Fujita, Kazutoshi and Azuma, Haruhito and Araki, Motoo and Inamoto, Teruo and Komura, Kazumasa and Kimura, Takahiro and JK-FOOT study group, JK-FOOT study group},
  title = {A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {3},
  doi = {10.1007/s00262-025-04288-6}
}
Kostenlos starten →